. 2022 Feb 24;14(5):1173. doi: 10.3390/cancers14051173

Table 3.

Pre-infection clinical and laboratory parameters in hematological patients hospitalized or not hospitalized for concomitant COVID-19.

Clinical and Laboratory Parameters Prior to COVID-19 Infection	Hospitalized	Not Hospitalized	p-Value ^a,b
Patients, N (%)	22 (26)	64 (74)
Age, years median (range)	71 (31–87)	63.5 (24–94)	*0.02 ^b*
Sex, n (%)
Female	8 (36)	37 (55)	0.14 ^a
Male	14 (66)	27 (45)
Charlson comorbidity index
Median (range)	5 (0–13)	3 (0–14)	NA
Coexisting condition, N (%)
Heart disease	10 (46)	12 (19)	*0.01 ^a*
Pulmonary disease	7 (23)	9 (14)	0.32 ^a
Vascular disease	7 (23)	10 (16)	0.46 ^a
Connective tissue disease	1 (5)	0 (0)	0.26 ^a
Liver disease	1 (5)	0 (0)	0.2 ^a
Diabetes	6 (27)	8 (13)	0.13 ^a
Non-hematological cancer	1 (5)	5 (9)	0.98 ^a
Type of hematological malignancies, N (%)
Myeloid neoplasms	4 (18)	16 (25)	0.56 ^a
Lymphoid neoplasms	9 (41)	20 (32)	0.60 ^a
Plasma Cell Neoplasms	9 (41)	28 (44)	0.99 ^a
Active therapy, N (%)	10 (46)	18 (30)	0.20 ^a
Last therapy type, N (%)
Chemotherapy	9 (41)	11 (18)	*0.04 ^a*
Immunotherapy	0	1 (2)	0.98 ^a
Targeted therapy	1 (5)	9 (14)	*0.04 ^a*
Hb, g/dL	11.8	12.8
median (IQR)	10.4- 13.1	11.5–14.0	*0.03 ^b*
ANC, ×10³ cells/uL	3.1	3.6
median (IQR)	1.3–6.9	2.3–4.6	0.57 ^b
ALC, ×10³ cells/uL	1.4	1.6
median (IQR)	0.9–3.5	1.0–2.4	0.92 ^b
AMC, ×10³ cells/uL	0.3	0.5
median (IQR)	0.07–0.5	0.3–0.6	*0.02 ^b*
Platelets × 10⁹ count/uL	183	199
median (IQR)	98–283	138–311	0.42 ^b
C-RP, IU/L	4.5	1.3-
median (IQR)	1.2–11.4	0.5–3.2	*0.002 ^b*
LDH, IU/L	221	197
median (IQR)	183–273	156–246	0.15 ^b

^a based on Fisher-exact test, ^b based on Mann–Whitney test. Results are reported as median and interquartile range (IQR). Abbreviations: Hb, hemoglobin; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; uL, micro-liter; IU/L, international units per liter; LDH, lactate de-hydrogenase; C-RP, C-reactive protein; NA, not available.